CAPR Posts Zero Revenue, $24.5M Loss But Hints at 2026 FDA Shot

Capricor (CAPR), a clinical-stage biotechnology company, reported its fiscal 2025 Q3 earnings on March 17, 2026, with results underscoring deepening financial challenges. The company’s net loss widened to $24.57 million, a 95.7% year-over-year increase, while revenue plummeted to $0 from $2.26 million. Guidance for the quarter was absent, with CEO David Pyott emphasizing operational efficiency and pipeline advancement as priorities.

Revenue

The total revenue of Capricor decreased by 100.0% to $0 in 2025 Q3, down from $2.26 million in 2024 Q3.

Earnings/Net Income

Capricor's losses deepened to $0.54 per share in 2025 Q3 from a loss of $0.38 per share in 2024 Q3 (42.1% wider loss). Meanwhile, the company's net loss widened to $-24.57 million in 2025 Q3, representing a 95.7% increase from the $-12.56 million loss recorded in 2024 Q3. The Company has sustained losses for 12 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. The EPS and net loss both deteriorated significantly, underscoring persistent financial challenges.

Price Action

The stock price of Capricor has edged up 1.73% during the latest trading day, has dropped 6.62% during the most recent full trading week, and has surged 38.93% month-to-date.

Post-Earnings Price Action Review

The strategy of buying Capricor (CAPR) shares after its revenue equal quarter-over-quarter on the financial report released date and holding for 30 days delivered strong returns over the past three years. The strategy achieved a 159.78% return, significantly outperforming the benchmark return of 49.27%. The excess return was 110.52%, indicating the strategy's ability to capitalize on the company's growth potential. The CAGR was 27.20%, reflecting consistent growth over the period. However, the strategy also experienced high volatility, with a maximum drawdown of 78.33% and a Sharpe ratio of 0.22, suggesting that while the returns were impressive, so were the risks.

CEO Commentary

Capricor CEO David Pyott emphasized the company’s focus on advancing its pipeline amid ongoing operational challenges, noting, “Our teams remain committed to executing on key milestones despite the current financial pressures.” He highlighted strategic investments in clinical development for its lead programs, including the Phase 3 trial for CAP-100 for Duchenne muscular dystrophy, as a critical growth driver. Pyott acknowledged the Q3 financial performance, stating, “The absence of revenue and significant net loss underscore the need for disciplined cost management and accelerated path toward commercialization.” On leadership outlook, he struck a cautiously optimistic tone, reiterating confidence in the long-term potential of the pipeline while stressing the importance of near-term data readouts to rebuild stakeholder confidence.

Guidance

Capricor provided no explicit quantitative guidance for 2025 Q3, citing the absence of revenue and a net loss of $24.57 million. The CEO reiterated a focus on advancing clinical trials and optimizing operational efficiency, stating, “We remain committed to de-risking our pipeline through key data events while managing cash burn.” Qualitative expectations centered on maintaining R&D momentum and exploring strategic partnerships to accelerate commercial readiness, though no specific financial targets or timelines were disclosed.

Additional News

Capricor Therapeutics (CAPR) announced positive Phase 3 HOPE-3 trial data for Deramiocel, its therapy for Duchenne muscular dystrophy, on March 12, 2026. The trial demonstrated statistically significant improvements in cardiac function, reduced myocardial fibrosis, and slowed disease progression in daily activities, including an 83% reduction in functional decline. These results, combined with Orphan Drug and Regenerative Medicine Advanced Therapy designations, position Deramiocel for potential FDA approval by August 22, 2026. The company also reported a $318 million cash balance as of Q4 2025, doubling from $151.5 million, providing liquidity through Q4 2027.